Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016
Cited by 1,004 works. doi:10.1016/s0140-6736(16)00004-0 Open-access PDF
Authors
- Fabrice Barlési
- Julien Mazières
- Jean‐Philippe Merlio
- Didier Debieuvre
- Jean Mosser
- H. Léna
- L’Houcine Ouafik
- Benjamin Besse
- Isabelle Rouquette
- Virginie Westeel
- Fabienne Escande
- I. Monnet
- Antoinette Lemoine
- Rémi Veillon
- Hélène Blons
- Clarisse Audigier-Valette
- Pierre‐Paul Bringuier
- R. Lamy
- Michèle Beau‐Faller
- Jean-Louis Pujol
References
- Hallmarks of Cancer: The Next Generation
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Cancer statistics, 2013
- Signatures of mutational processes in human cancer
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
- Comprehensive molecular profiling of lung adenocarcinoma
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up